NCT06695221Recruiting
Improving Health Outcomes With Kefir
Source: ClinicalTrials.gov · Last updated 8 May 2026
Brief summary (registry, in English)
The purpose of the study is to ascertain whether traditional kefir not only enhances vascular health but also contributes to improved immune outcomes in both male and female participants at higher risk or living with Type 2 Diabetes (T2D) after 12 weeks of treatment.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 156 (estimated)
- First submitted
- 13 Nov 2024
- Start date
- 24 Mar 2026
- Primary completion date
- Dec 2027
- Lead sponsor
- University of Alberta
- Diseases
- Type 2 diabetes
- NCT number
- NCT06695221
What you commit to
- Study type: Interventional
- Planned participants: 156
- From 24 Mar 2026 to the primary completion date, Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- use of medications within the last 3 months (i.e., antibiotics or antifungals, corticosteroids, methotrexate, or immunosuppressive cytotoxic agents);
Other illness
- gastrointestinal (GI) disorders of any kind;
- monogenic dyslipidemias and endocrine disorders except for diabetes;
- any health conditions deemed to interfere with primary outcomes at the investigator's discretion (e.g., kidney disease, liver disease, cancer, GI surgery, heavy alcohol consumption, etc.);
Other
- a usual high intake (maximum intake 3 servings/week) of fermented foods excluding cheese (i.e., kefir, kombucha, kimchi, etc.) for the past 3 months;
- being pregnant or breastfeeding;
- having a pacemaker or any electrical medical device that prevents the individual from undergoing the bioelectrical impedance analysis bioimmunoassay (BIA) test."
Who the study is looking for
- females and males (24-70 years old) living in Edmonton (or Edmonton area/driving distance);
- overweight or obesity (BMI \>25 Caucasian, \>23 Asian);
- at higher risk of T2D (fasting blood glucose ≥ 5.6 - 6.9 mmol/L or/and HbA1C ≥ 5.5 - 6.4%); or
- with diagnosis of T2D (fasting blood glucose ≥ 7.0 mmol/L or/and HbA1C ≥ 6.5%).
Age in the registry: 24 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Alberta Coordinator of this site? Confirm its status | Edmonton | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.